<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<ns2:studies xmlns:ns2="http://webservice.caaers.cabig.nci.nih.gov">
    <ns2:study>
        <shortTitle>A Phase I Study of CCI-779 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme</shortTitle>
        <longTitle>A Phase I Study of CCI-779 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme</longTitle>
        <description>A Phase I Study of CCI-779 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiformexxxx</description>
        <phaseCode>Phase I Trial</phaseCode>
        <status>Active - Trial is open to accrual</status>
        <multiInstitutionIndicator>true</multiInstitutionIndicator>
        <adeersReporting>true</adeersReporting>
        <otherMeddra>MedDRA v9</otherMeddra>
        <ns2:aeTerminology>
            <ns2:ctcVersion>
                <name>3</name>
            </ns2:ctcVersion>
        </ns2:aeTerminology>
        <ns2:diseaseTerminology>
            <diseaseCodeTerm>CTEP</diseaseCodeTerm>
        </ns2:diseaseTerminology>
        <drugAdministrationTherapyType>true</drugAdministrationTherapyType>
        <deviceTherapyType>true</deviceTherapyType>
        <radiationTherapyType>true</radiationTherapyType>
        <surgeryTherapyType>false</surgeryTherapyType>
        <behavioralTherapyType>false</behavioralTherapyType>
        <biologicalTherapyType>false</biologicalTherapyType>
        <geneticTherapyType>false</geneticTherapyType>
        <dietarySupplementTherapyType>false</dietarySupplementTherapyType>
        <otherTherapyType>false</otherTherapyType>
        <reportTypeCaaersXML>true</reportTypeCaaersXML>
        <reportTypeAdeersPDF>true</reportTypeAdeersPDF>
        <reportTypeMedwatchPDF>false</reportTypeMedwatchPDF>
        <reportTypeDCPSAEForm>false</reportTypeDCPSAEForm>
        <reportTypeCIOMSForm>false</reportTypeCIOMSForm>
        <reportTypeCIOMSAEForm>false</reportTypeCIOMSAEForm>
        <fundingSponsor>
            <organizationAssignedIdentifier>
                <value>N027D</value>
            </organizationAssignedIdentifier>
            <ns2:studyFundingSponsor>
                <ns2:organization>
                    <name>Cancer Therapy Evaluation Program</name>
                    <nciInstituteCode>CTEP</nciInstituteCode>
                </ns2:organization>
            </ns2:studyFundingSponsor>
        </fundingSponsor>
        <coordinatingCenter>
            <organizationAssignedIdentifier>
                <value>N027D</value>
            </organizationAssignedIdentifier>
            <ns2:studyCoordinatingCenter>
				<ns2:organization>
					<name>Kenyatta National Hospital</name>
					<nciInstituteCode>100001</nciInstituteCode>
				</ns2:organization>
			</ns2:studyCoordinatingCenter>
        </coordinatingCenter>
      <studyOrganizations>
			<ns2:studySite>
				<ns2:organization>
					<name>Karnataka Cancer Therapy and Research Institute</name>
					<nciInstituteCode>37007</nciInstituteCode>
				</ns2:organization>
				<studyInvestigators>
					<ns2:studyInvestigator>
						<roleCode>SI</roleCode>
						<startDate>2010-01-01</startDate>
						<ns2:siteInvestigator>
							<ns2:investigator>
								<firstName>John</firstName>
								<lastName>inv1</lastName>
								<nciIdentifier>inv-5876-v1</nciIdentifier>
							</ns2:investigator>
						</ns2:siteInvestigator>
					</ns2:studyInvestigator>
				</studyInvestigators>
				<studyPersonnels>
					<ns2:studyPersonnel>
						<roleCode>caaers_participant_cd</roleCode>
						<startDate>2009-08-31</startDate>
						<endDate>2011-02-01</endDate>
						<ns2:researchStaff>
							<firstName>robert</firstName>
							<lastName>rs1</lastName>
							<nciIdentifier>rs-5876-v1</nciIdentifier>
						</ns2:researchStaff>
					</ns2:studyPersonnel>
					<ns2:studyPersonnel>
						<roleCode>caaers_ae_cd</roleCode>
						<startDate>2009-08-31</startDate>
						<ns2:researchStaff>
							<firstName>robert</firstName>
							<lastName>rs1</lastName>
							<nciIdentifier>rs-5876-v1</nciIdentifier>
						</ns2:researchStaff>
					</ns2:studyPersonnel>
				</studyPersonnels>
			</ns2:studySite>
		</studyOrganizations>
        <identifiers/>
        <treatmentAssignments>
            <ns2:treatmentAssignment>
                <code>A0</code>
                <description>Concomitant Treatment      Cycle = 6 weeks:    CCI-779:  25mg/wk IV over 30 min weekly RT:  200cGy 5 days a wk, starting 7-10 days after first CCI-779 dose TMZ:  75mg/m2 PO QD with RT  Adjuvant Treatment     Cycle = 28 days     (Max = 6 cycles) CCI-779:</description>
            </ns2:treatmentAssignment>
            <ns2:treatmentAssignment>
                <code>A0 A</code>
                <description>Concomitant Treatment      Cycle = 6 weeks:    CCI-779:  25mg/wk IV over 30 min weekly RT:  200cGy 5 days a wk, starting 7-10 days after first CCI-779 dose TMZ:  75mg/m2 PO QD with RT  Adjuvant Treatment     Cycle = 28 days     (Max = 6 cycles) TMZ:  200m</description>
            </ns2:treatmentAssignment>
            <ns2:treatmentAssignment>
                <code>A1</code>
                <description>Concomitant Treatment      Cycle = 6 weeks: CCI-779:  50mg/wk IV over 30 min weekly RT:  200cGy 5 days a wk, starting 7-10 days after first CCI-779 dose TMZ:  75mg/m2 PO QD with RT   Adjuvant Treatment      Cycle = 28 days:     (Max = 6 cycles) CCI-779:</description>
            </ns2:treatmentAssignment>
            <ns2:treatmentAssignment>
                <code>A-1</code>
                <description>Concomitant Treatment      Cycle = 6 weeks: CCI-779:  15mg/wk IV over 30 min weekly RT:  200cGy 5 days a wk, starting 7-10 days after first CCI-779 dose TMZ:  75mg/m2 PO QD with RT  Adjuvant Treatment:      Cycle = 28 days:     (Max = 6 cycles) TMZ:  200m</description>
            </ns2:treatmentAssignment>
            <ns2:treatmentAssignment>
                <code>A1 A</code>
                <description>Concomitant Treatment      Cycle = 6 weeks: CCI-779:  50mg/wk IV over 30 min weekly RT:  200cGy 5 days a wk, starting 7-10 days after first CCI-779 dose TMZ:  75mg/m2 PO QD with RT  Adjuvant Treatment      Cycle = 28 days:     (Max = 6 cycles) TMZ:  200mg</description>
            </ns2:treatmentAssignment>
            <ns2:treatmentAssignment>
                <code>A2</code>
                <description>Concomitant Treatment:      Cycle = 6 weeks: CCI-779:  75mg/wk IV over 30 min weekly RT:  200cGy 5 days a wk, starting 7-10 days after first CCI-779 dose TMZ:  75mg/m2 PO QD with RT  Adjuvant Treatment:     Cycle = 28 days, max 6 cycles CCI-779:  75mg/wk</description>
            </ns2:treatmentAssignment>
            <ns2:treatmentAssignment>
                <code>A-2</code>
                <description>Concomitant Treatment Cycle = 6 weeks: CCI-779:  15mg/wk IV over 30 min weekly RT:  200cGy 5 days a wk, starting 7-10 days after first CCI-779 dose TMZ:  60mg/m2 PO QD with RT  Adjuvant Treatment       Cycle = 28 days     (Max = 6 cycles) TMZ:  200mg/m2 P</description>
            </ns2:treatmentAssignment>
            <ns2:treatmentAssignment>
                <code>A2 A</code>
                <description>Concomitant Treatment      Cycle = 6 weeks: CCI-779:  75mg/wk IV over 30 min weekly RT:  200cGy 5 days a wk, starting 7-10 days after first CCI-779 dose TMZ:  75mg/m2 PO QD with RT  Adjuvant Treatment Cycle = 28 days:     (Max = 6 cycles) TMZ:  200mg/m2 P</description>
            </ns2:treatmentAssignment>
            <ns2:treatmentAssignment>
                <code>A3</code>
                <description>Concomitant Treatment      Cycle = 6 weeks: CCI-779:  125mg/wk IV over 30 min weekly RT:  200cGy 5 days a wk, starting 7-10 days after first CCI-779 dose TMZ:  75mg/m2 PO QD with RT  Adjuvant Treatment Cycle = 28 days:     (Max = 6 cycles) TMZ:  200mg/m2</description>
            </ns2:treatmentAssignment>
            <ns2:treatmentAssignment>
                <code>A4</code>
                <description>Concomitant Treatment      Cycle = 6 weeks: CCI-779:  175mg/wk IV over 30 min weekly RT:  200cGy 5 days a wk, starting 7-10 days after first CCI-779 dose TMZ:  75mg/m2 PO QD with RT  Adjuvant Treatment      Cycle = 28 days:     (Max = 6 cycles) TMZ:  200m</description>
            </ns2:treatmentAssignment>
            <ns2:treatmentAssignment>
                <code>A5</code>
                <description>Concomitant Treatment Cycle = 6 weeks: CCI-779:  250mg/wk IV over 30 min weekly RT:  200cGy 5 days a wk, starting 7-10 days after first CCI-779 dose TMZ:   75mg/m2 PO QD with RT  Adjuvant Treatment      Cycle = 28 days:     (Max = 6 cycles) TMZ:  200mg/m2</description>
            </ns2:treatmentAssignment>
            <ns2:treatmentAssignment>
                <code>B1</code>
                <description>Concomitant Treatment Cycle = 6 weeks: RT:  200cGy 5 days a wk TMZ:   75mg/m2 PO QD   Adjuvant Treatment      Cycle = 28 days:     (Max = 6 cycles) TMZ:  200mg/m2 PO on days 1-5</description>
            </ns2:treatmentAssignment>
        </treatmentAssignments>
        <studyAgents>
            <ns2:studyAgent>
                <ns2:agent>
                    <name>CCI-779 (temsirolimus, Torisel)</name>
                </ns2:agent>
                <indType>CTEP_IND</indType>
                <partOfLeadIND>true</partOfLeadIND>
                <studyAgentINDAssociations>
                    <ns2:studyAgentINDAssociation>
                        <ns2:investigationalNewDrug>
                            <indNumber>-111</indNumber>
                        </ns2:investigationalNewDrug>
                    </ns2:studyAgentINDAssociation>
                </studyAgentINDAssociations>
            </ns2:studyAgent>
            <ns2:studyAgent>
                <ns2:agent>
                    <name>Temozolomide</name>
                </ns2:agent>
                <indType>NA_COMMERCIAL</indType>
            </ns2:studyAgent>
        </studyAgents>
        <ctepStudyDiseases>
            <ns2:ctepStudyDisease>
                <ns2:diseaseTerm>
                    <term>Glioblastoma multiforme</term>
                </ns2:diseaseTerm>
                <leadDisease>true</leadDisease>
            </ns2:ctepStudyDisease>
        </ctepStudyDiseases>
        <evaluationPeriods>
            <ns2:evaluationPeriod>
                <name>Baseline</name>
                <epochOrder>0</epochOrder>
                <solicitedAdverseEvents>
                    <ns2:solicitedAdverseEvent>
                        <ctepCode>10059095</ctepCode>
                    </ns2:solicitedAdverseEvent>
                    <ns2:solicitedAdverseEvent>
                        <ctepCode>10063190</ctepCode>
                    </ns2:solicitedAdverseEvent>
                </solicitedAdverseEvents>
            </ns2:evaluationPeriod>
            <ns2:evaluationPeriod>
                <name>Treatment</name>
                <epochOrder>1</epochOrder>
                <solicitedAdverseEvents>
                    <ns2:solicitedAdverseEvent>
                        <ctepCode>10063190</ctepCode>
                    </ns2:solicitedAdverseEvent>
                    <ns2:solicitedAdverseEvent>
                        <ctepCode>10015453</ctepCode>
                    </ns2:solicitedAdverseEvent>
                </solicitedAdverseEvents>
            </ns2:evaluationPeriod>
            <ns2:evaluationPeriod>
                <name>Post-treatment</name>
                <epochOrder>2</epochOrder>
                <solicitedAdverseEvents>
                    <ns2:solicitedAdverseEvent>
                        <ctepCode>10059095</ctepCode>
                    </ns2:solicitedAdverseEvent>
                    <ns2:solicitedAdverseEvent>
                        <ctepCode>10015453</ctepCode>
                    </ns2:solicitedAdverseEvent>
                </solicitedAdverseEvents>
            </ns2:evaluationPeriod>
        </evaluationPeriods>
        <expectedAECtcTerms>
            <ns2:expectedAECtcTerm>
                <ctepCode>10010774</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10050857</ctepCode>
            </ns2:expectedAECtcTerm>
            <ns2:expectedAECtcTerm>
                <ctepCode>10012727</ctepCode>
            </ns2:expectedAECtcTerm>
        </expectedAECtcTerms>
    </ns2:study>
</ns2:studies>
